Related Experiment Video
Updated: Jun 16, 2026
09:48
Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Hypoadiponectinemia--cause or consequence of human "insulin resistance"?
Joshua R Cook1, Robert K Semple
1University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Treatment Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 OQQ, United Kingdom.
The Journal of Clinical Endocrinology and Metabolism
|February 19, 2010
Summary
The relationship between adiponectin and insulin resistance in humans is complex and potentially bidirectional. Further research is needed to clarify causality and therapeutic potential.
Area of Science:
- Endocrinology
- Metabolic Syndrome Research
Background:
- Adiponectin, a protein synthesized in adipose tissue, correlates with insulin resistance (IR) and type 2 diabetes risk.
- Its inverse relationship with fat mass and potential as a therapeutic target for insulin sensitization has generated significant interest.
Purpose of the Study:
- To investigate the complex relationship between adiponectin and insulin action in humans.
- To explore the direction of causality and cellular mechanisms involved.
Main Methods:
- Systematic literature review of relevant publications.
- PubMed database search with secondary bibliography review.
Main Results:
- Rodent studies indicate adiponectin's direct insulin-sensitizing effect on the liver.
- Evidence in humans suggests low adiponectin may be a consequence of IR with compensatory hyperinsulinemia, indicating a bidirectional relationship.
- The precise role and receptors of adiponectin in humans remain complex and not fully elucidated.
Conclusions:
- The adiponectin-insulin action link in humans is more intricate than previously assumed.
- Clarifying the causal direction and cellular mechanisms is crucial for understanding adiponectin's physiological role.
- Further research is essential for potential therapeutic applications targeting adiponectin.
Related Concept Videos
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...